Today, Novavax is excited to announce the results of PREVENT-19 Phase 3. # Clinical trial The United States and Mexico are evaluating the safety and efficacy of NVX-CoV2373. # COVI19 #vaccine candidate. yarn: pic.twitter.com/ZuTEBO18wB
— Novavax (@Novavax) June 14, 2021
Novavax Inc (Nasdaq: NVAX) announced on Monday that the COVID-19 vaccine is highly effective against the virus while also protecting it from known variants in late-stage clinical trials in the United States and Mexico.
A Maryland-based biotechnology company states that vaccines are more than 90% effective overall and 100% preventive against moderate to severe illnesses. Press release..
The study, which enrolled 29,960 participants, also showed that the vaccine was 93% effective against known variants of coronavirus.
According to the company, double-dose vaccines were “generally well tolerated,” with common side effects of less than 3 days of pain at the injection site and less than 2 days of malaise, headache, and muscle aches.
“These data show consistently high levels of efficacy and vaccines that prevent COVID-19 during the ongoing genetic evolution of the virus,” said Gregory Glenn, Head of Research and Development at Novavax, in a statement. We are reaffirming our ability. “
“Our vaccine is an important part of the COVID-19 solution, and we thank the research participants and study staff who made the study possible, and our supporters, including the US Government,” he said. I did.
The company’s vaccine, called NVX-CoV2373, differs from the three vaccines already in use in the United States. CNN OK.
Novavax vaccine Recombinant nanoparticle technology and adjuvant Stimulates the immune response.
Two mRNA vaccines issued by Moderna and Pfizer-BioNTech in the United States last year use genetic material to stimulate the immune response.
The Johnson & Johnson single-shot vaccine, approved in February, uses a weakened common cold virus as a vector to convey genetic instructions.
Faced with a shortage of raw materials that impacted production, Novabax plans to apply for an emergency use authorization for the vaccine in the United States in the third quarter of this year, saying production is “on track.” 100 million doses per month By the end of the third quarter.
Demand for the COVID-19 vaccine is declining in the United States, but the need for injections in other parts of the world remains high. According to a data collection effort partially carried out by the University of Oxford 1% of people in developing countries I was vaccinated once.
According to the Associated Press, the Novavax vaccine, which can be stored in a regular refrigerator, is expected to play an important role in promoting its global supply.
Novavax CEO and President Stanley Erck told the media: [from the beginning].. “
Last month, Gavi, the leader of a UN-sponsored COVAX project that supplies shots to poor countries, announced that it had signed a purchase deal. 350 million times Of the Novavax vaccine.
Source: Equity news